Evaluation of Fractional Bipolar Radiofrequency for the Treatment of Striae

December 30, 2013 updated by: Candela France

Evaluation of Fractional Bipolar Radiofrequency, and Bipolar Radiofrequency Potentiated by Infrared, in Monotherapy or Combined, for the Treatment of Striae

This is an interventional open prospective randomized study, done in two sites.

The main purpose of this study is to evaluate the efficacy of the combination of bipolar radiofrequency potentiated by an infrared light followed by fractional bipolar radiofrequency for the treatment of striae on the abdomen.

In order to have a more complete and accurate study, each technology will also be evaluated separately. This will allow the comparison of the effect of each treatment, in monotherapy or combined.

Study Overview

Detailed Description

Stria is a very common condition that affects psychologically and aesthetically a lot of patients. It is a linear atrophic scar. So, to be treated, it needs to have both a superficial and a deep impact.

Several technologies have already been tested for this indication, but none of them have been proved at the same time effective and without a high risk of side effects for all skin types. As radiofrequency is an electrical current, it is not absorbed and does not see melanin. So it can be used on all skin types.

When using fractional bipolar radiofrequency, the current goes from small electrodes to return electrodes. Around the small electrodes appear some epidermal ablation, coagulation and deeper thermal damage. This means it has a superficial and a deep effect.

Using infrared combined with bipolar radiofrequency allows the infrared to pre-heat the skin so as to help the radiofrequency to go deeper in the skin more easily. This has a deep effect in the dermis.

In this study, both technologies will be used. At least 20 patients will be treated in two different sites.

The abdomen of each patient will be divided in four quadrants around the navel. Each quadrant will receive a total of three treatments one month apart:

  • One quadrant will be the control (no treatment will be done)
  • One quadrant will receive each time only bipolar radiofrequency potentiated by infrared
  • One quadrant will receive each time only fractional bipolar radiofrequency
  • One quadrant will receive each time first bipolar radiofrequency potentiated by infrared, followed in the same session by fractional bipolar radiofrequency.

The choice of the treatment for each area will be randomized at the enrollment of the patient in the study.

There will be two follow-up sessions 3 and 6 months after the last treatment.

The evaluation will be done mainly by 3D acquisitions. This will allow measuring the length, width and depth of the striae and evaluating their evolution after the treatment.

Some patients, if they agree, will also have in vivo confocal microscopy before the first treatment and 6 months after the last one. This will give more information on the collagen and elastin changes.

Four patients, who accept it, will have biopsies performed before the first treatment and 6 months after the last one to also show the evolution of the skin structure.

Study Type

Interventional

Enrollment (Actual)

22

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bordeaux, France, 33200
        • Aesthetics
      • Nice, France, 06200
        • CHU Archet II, Service de Dermatologie

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male and female subject over 18 years old, with striae on all the abdomen (white or red)
  • Consent form signed by subjects
  • Affiliation to social security

Exclusion Criteria:

  • Electrical implants (pace maker, defibrillator) or superficial metallic implants (gold thread…)
  • Pregnant woman
  • Woman who can procreate without using an effective birth control
  • Deficient immune system due to immunosuppressive diseases such as AIDS or HIV, or use of immunosuppressive drugs,
  • Stretch marks resulting from treatment with steroids,
  • Treatment with oral retinoids ongoing or stopped less than a year ago, or photosensitizing ongoing or stopped less than 3 months ago
  • History of diseases stimulated by heat (recurrent herpes) on the treatment area
  • Procedure less than 6 months ago performed on the treatment area,
  • History of keloid scarring or difficulty in healing,
  • History of allergy to xylocaine (for subjects who will have biopsy)
  • Dermatological disorder requiring systemic therapy or local therapy in the area under study,
  • Systemic disease in evolution (cancer or history of cancer, heart disease, uncontrolled diabetes, pain syndrome, history of neuropathy)
  • Problem of coagulation and / or anticoagulant therapy,
  • Vascular lesions or tattoos on the treatment area,
  • Vulnerable Person: minor, under protection, deprived of liberty.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: bipolar radiofrequency and infrared
The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive only bipolar radiofrequency potentiated by infrared, 3 treatments one month apart.
Other Names:
  • Applicator Sublime on the platform eTwo
Active Comparator: fractional bipolar radiofrequency
The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive only fractional bipolar radiofrequency , 3 treatments one month apart.
Other Names:
  • applicator Sublative, platform eTwo
Active Comparator: combined treatment
The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive first bipolar radiofrequency potentiated by infrared, followed in the same session by fractional bipolar radiofrequency, 3 treatments one month apart.
Other Names:
  • Applicator Sublime on the platform eTwo
Other Names:
  • applicator Sublative, platform eTwo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of striae volume
Time Frame: before the first treatment, 3 and 6 months after the last treatment. Months 0, 5 and 8
The stretch marks in each area will be evaluated with a 3D camera (Antera 3D, Miravex). This will give access to the length, width and depth of each stria. Those measurements will then be compared so as to evaluate each technology.
before the first treatment, 3 and 6 months after the last treatment. Months 0, 5 and 8

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Observation of the skin structure changes with in vivo confocal microscopy
Time Frame: 5 months
In vivo confocal microscopy acquisitions will be done on all subjects who agree to do so. It is a non-invasive imaging procedure that shows the different structures of the skin (such as collagen fibers and elastin). This will allow us to assess the effect of both technologies, used in monotherapy or combined, on those structures.
5 months
Observation of the skin structure changes with in vivo confocal microscopy
Time Frame: 8 months
In vivo confocal microscopy acquisitions will be done on all subjects who agree to do so. It is a non-invasive imaging procedure that shows the different structures of the skin (such as collagen fibers and elastin). This will allow us to assess the effect of both technologies, used in monotherapy or combined, on those structures.
8 months
Observation of the skin structure changes by histology
Time Frame: 8 months
For four patients, who previously agreed to do so, 3 biopsies will be done (one on each quadrant that will receive a treatment) before any treatment and at the 6 month follow-up session. They will be analyzed in the anatomopathology laboratory of the Archet II hospital. It will show the entire dermal and epidermal evolution after each type of treatment.
8 months
Pain assessment
Time Frame: 1 month
Pain will be assessed with an analogical visual scale.
1 month
Pain assessment
Time Frame: 2 months
Pain will be assessed with an analogical visual scale.
2 months
Global satisfaction
Time Frame: 1 month
The global satisfaction of both the subject and the investigator will be assessed with an analogical visual scale.
1 month
Global satisfaction
Time Frame: 2 months
The global satisfaction of both the subject and the investigator will be assessed with an analogical visual scale.
2 months
Double blinded pictures observation
Time Frame: 5 months
Standardized pictures will be taken at the beginning of each session. Two external doctors will evaluate each picture on a Physician Global Assessment scale, without knowing to which session or to which subject it corresponds.
5 months
Double blinded pictures observation
Time Frame: 8 months
Standardized pictures will be taken at the beginning of each session. Two external doctors will evaluate each picture on a Physician Global Assessment scale, without knowing to which session or to which subject it corresponds.
8 months
global satisfaction
Time Frame: 5 months
The global satisfaction of both the subject and the investigator will be assessed with an analogical visual scale.
5 months
Global satisfaction
Time Frame: 8 months
The global satisfaction of both the subject and the investigator will be assessed with an analogical visual scale.
8 months
Pain assessment
Time Frame: first day
Pain will be assessed with an analogical visual scale.
first day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Thierry Passeron, Pr, Hopital Archet II, service de Dermatologie

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2013

Primary Completion (Actual)

November 1, 2013

Study Completion (Actual)

November 1, 2013

Study Registration Dates

First Submitted

February 5, 2013

First Submitted That Met QC Criteria

February 8, 2013

First Posted (Estimate)

February 11, 2013

Study Record Updates

Last Update Posted (Estimate)

December 31, 2013

Last Update Submitted That Met QC Criteria

December 30, 2013

Last Verified

December 1, 2013

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PRB-E2VER02
  • 2012-A01427-36 (Other Identifier: ANSM (French health committee))
  • 12.084 (Other Identifier: CPP Sud Méditerranée V (ethics committee))

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Striae

Clinical Trials on bipolar radiofrequency and infrared

3
Subscribe